stock

Abbvie Inc (ABBV)

Share

Stay up to date

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.

Financial Statements

Key Info

  • Industry: Pharmaceutical Preparation Manufacturing
  • Sector: Manufacturing
  • CEO Name: Richard Gonzalez

Key Statistics

  • Stock Price: $149.06
  • Dividend Yield: 3.9%
  • Market Capitalization: $263,097,858,121
  • Shares Outstanding: 1,765,046,680
  • Number of Employees: 50,000
  • Trailing 12-Month EPS: $4.87
  • Trailing 12-Month DPS: $5.76
  • Payout Ratio: 118.30000000000001%

Important Dates

  • Next Earnings Date: 2023-10-27
  • Next Ex-Dividend Date: 2023-07-13

Price Trends

  • Current Stock Price: $149.06
  • 52-week high: $164.38
  • 52-week low: $129.52
  • 200-day moving average: $146.48
  • 50-day moving average: $150.25

Performance

  • 1-Month Price Return: 1.0%
  • 3-Month Price Return: 13.1%
  • 6-Month Price Return: -3.7%
  • 1-Year Price Return: 8.7%
  • 2-Year Price Return: 48.3%
  • 5-Year Price Return: 99.2%

Visit the Passiv Stock Directory

Data provided by IEX Cloud

For Canadian securities, listen to free conference calls on the TSX Quarterly Podcast